Alexandria Co. For Pharmaceuticals & Chemical Industries

CASE:AXPH Stock Report

Market Cap: ج.م1.2b

Alexandria For Pharmaceuticals & Chemical Industries Past Earnings Performance

Past criteria checks 4/6

Alexandria For Pharmaceuticals & Chemical Industries's earnings have been declining at an average annual rate of -0.03%, while the Pharmaceuticals industry saw earnings growing at 9.8% annually. Revenues have been growing at an average rate of 13.2% per year. Alexandria For Pharmaceuticals & Chemical Industries's return on equity is 21%, and it has net margins of 9.3%.

Key information

-0.03%

Earnings growth rate

1.1%

EPS growth rate

Pharmaceuticals Industry Growth9.8%
Revenue growth rate13.2%
Return on equity21.0%
Net Margin9.3%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Alexandria For Pharmaceuticals & Chemical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CASE:AXPH Revenue, expenses and earnings (EGP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 231,628151330
30 Jun 231,484126840
30 Sep 221,154123780
30 Jun 221,100117760
31 Mar 221,06389830
31 Dec 211,10895870
30 Sep 211,095101880
30 Jun 211,104117940
31 Mar 211,116144910
31 Dec 201,074164870
30 Sep 201,073177910
30 Jun 201,025170860
31 Mar 20964143830
31 Dec 19906126790
30 Sep 19871120710
30 Jun 19829113670
31 Mar 19781117650
31 Dec 18776119610
30 Sep 18746112590
30 Jun 18704118570
31 Mar 18682124820
31 Dec 17633127720
30 Sep 17558107600
30 Jun 1751191500
31 Mar 1750897450
31 Dec 1645774130
30 Sep 1643377130
30 Jun 1641972130
31 Mar 1639960430
31 Dec 1539465430
30 Sep 1538862430
30 Jun 1537759430
31 Mar 1536856110
31 Dec 1435253110
30 Sep 1432949110
30 Jun 1430848100
31 Mar 1430748100
31 Dec 133014690
30 Sep 132964790
30 Jun 132894890
31 Mar 134714790

Quality Earnings: AXPH has high quality earnings.

Growing Profit Margin: AXPH's current net profit margins (9.3%) are lower than last year (10.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AXPH's earnings have declined by 0.03% per year over the past 5 years.

Accelerating Growth: AXPH's earnings growth over the past year (22.4%) exceeds its 5-year average (-0.03% per year).

Earnings vs Industry: AXPH earnings growth over the past year (22.4%) exceeded the Pharmaceuticals industry -4.3%.


Return on Equity

High ROE: AXPH's Return on Equity (21%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.